{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:24:53Z","timestamp":1786994693195,"version":"build-2736575974"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H00184"],"award-info":[{"award-number":["21H00184"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H02846"],"award-info":[{"award-number":["21H02846"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H05612"],"award-info":[{"award-number":["21H05612"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience & Biobehavioral Reviews"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.neubiorev.2022.104762","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T23:04:09Z","timestamp":1656543849000},"page":"104762","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["(R)-ketamine as prophylactic and therapeutic drug for neurological disorders: Beyond depression"],"prefix":"10.1016","volume":"139","author":[{"given":"Xingming","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neubiorev.2022.104762_bib1","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6635084","article-title":"Ketamine induces lasting antidepressant effects by modulating the NMDAR\/CaMKII-mediated synaptic plasticity of the hippocampal dentate gyrus in depressive stroke model","volume":"2021","author":"Abdoulaye","year":"2021","journal-title":"Neural Plast."},{"key":"10.1016\/j.neubiorev.2022.104762_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.638651","article-title":"Depression in Alzheimer's disease: A Delphi Consensus on Etiology, Risk Factors, and Clinical Management","volume":"12","author":"Ag\u00fcera-Ortiz","year":"2021","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.neubiorev.2022.104762_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2020.113413","article-title":"Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia","volume":"333","author":"Bartlett","year":"2020","journal-title":"Exp. Neurol."},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104762_bib4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.neubiorev.2022.104762_bib5","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/jnr.24224","article-title":"Animal models of multiple sclerosis: Focus on experimental autoimmune encephalomyelitis","volume":"96","author":"Bjelobaba","year":"2018","journal-title":"J. Neurosci. Res."},{"issue":"11","key":"10.1016\/j.neubiorev.2022.104762_bib6","doi-asserted-by":"crossref","first-page":"6704","DOI":"10.1038\/s41380-021-01093-2","article-title":"Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability","volume":"26","author":"Bonaventura","year":"2021","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104762_bib7","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12974-019-1564-7","article-title":"The endotoxin hypothesis of neurodegeneration","volume":"16","author":"Brown","year":"2019","journal-title":"J. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104762_bib8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41420-022-01063-9","article-title":"Regulation of BDNF transcription by Nrf2 and MeCP2 ameliorates MPTP-induced neurotoxicity","volume":"8","author":"Cao","year":"2022","journal-title":"Cell Death Disco"},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104762_bib9","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000226578","article-title":"Osteoporosis after stroke: a review of the causes and potential treatments","volume":"28","author":"Carda","year":"2009","journal-title":"Cerebrovasc. Dis."},{"key":"10.1016\/j.neubiorev.2022.104762_bib10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jad.2021.01.056","article-title":"Treatment response and age of onset as risk indicators for Parkinson disease in patients with major depressive disorder: A nationwide longitudinal study","volume":"283","author":"Chan","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neubiorev.2022.104762_bib11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.brainresbull.2022.02.004","article-title":"Brain-gut-microbiota axis in depression: A historical overview and future directions","volume":"182","author":"Chang","year":"2022","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neubiorev.2022.104762_bib12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pbb.2019.04.008","article-title":"Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine","volume":"181","author":"Chang","year":"2019","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"7","key":"10.1016\/j.neubiorev.2022.104762_bib13","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s40273-021-01032-7","article-title":"Economic burden of multiple sclerosis in low- and middle-income countries: A systematic review","volume":"39","author":"Dahham","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.neubiorev.2022.104762_bib14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1192\/bjp.bp.112.118307","article-title":"Late-life depression and risk of vascular dementia and Alzheimer's disease: systematic review and meta-analysis of community-based cohort studies","volume":"202","author":"Diniz","year":"2013","journal-title":"Br. J. Psychiatry"},{"issue":"8","key":"10.1016\/j.neubiorev.2022.104762_bib15","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","article-title":"A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression","volume":"67","author":"Diazgranados","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104762_bib16","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/ALN.0b013e3181ed09a2","article-title":"Taming the ketamine tiger. 1965","volume":"113","author":"Domino","year":"2010","journal-title":"Anesthesiology"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104762_bib17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/STROKEAHA.111.630871","article-title":"Depression and risk of stroke: a meta-analysis of prospective studies","volume":"43","author":"Dong","year":"2012","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104762_bib18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0014-2999(97)01116-3","article-title":"Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord","volume":"333","author":"Ebert","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neubiorev.2022.104762_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577700","article-title":"The second brain: The connection between gut microbiota composition and multiple sclerosis","volume":"360","author":"Farshbafnadi","year":"2021","journal-title":"J. Neuroimmunol."},{"issue":"7","key":"10.1016\/j.neubiorev.2022.104762_bib20","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s41380-018-0256-5","article-title":"Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).","volume":"25","author":"Fava","year":"2020","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104762_bib21","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1474-4422(19)30411-9","article-title":"The global burden of neurological disorders: translating evidence into policy","volume":"19","author":"Feigin","year":"2020","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.neubiorev.2022.104762_bib22","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1177\/1352458511417835","article-title":"Multiple sclerosis and depression","volume":"17","author":"Feinstein","year":"2011","journal-title":"Mult. Scler."},{"issue":"7","key":"10.1016\/j.neubiorev.2022.104762_bib23","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1177\/1352458517702553","article-title":"Multiple sclerosis and suicide","volume":"23","author":"Feinstein","year":"2017","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.neubiorev.2022.104762_bib24","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1177\/1352458520936226","article-title":"Pilot randomized active-placebo-controlled trial of low-dose ketamine for the treatment of multiple sclerosis-related fatigue","volume":"27","author":"Fitzgerald","year":"2021","journal-title":"Mult. Scler."},{"issue":"12","key":"10.1016\/j.neubiorev.2022.104762_bib25","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nrn.2017.136","article-title":"Regenerating CNS myelin\u2013from mechanisms to experimental medicines","volume":"18","author":"Franklin","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104762_bib26","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00213-019-05346-5","article-title":"MPTP-induced dopaminergic neurotoxicity in mouse brain is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling","volume":"237","author":"Fujita","year":"2020","journal-title":"Psychopharmacol. (Berl. )"},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104762_bib27","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/npr2.12132","article-title":"Decreased bone mineral density in ovariectomized mice is ameliorated after subsequent repeated intermittent administration of (R)-ketamine, but not (S)-ketamine","volume":"40","author":"Fujita","year":"2020","journal-title":"Neuropsychopharmacol. Rep."},{"key":"10.1016\/j.neubiorev.2022.104762_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173954","article-title":"Dextran sulfate sodium-induced inflammation and colitis in mice are ameliorated by (R)-ketamine, but not (S)-ketamine: A role of TrkB signaling","volume":"897","author":"Fujita","year":"2021","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104762_bib29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1124\/jpet.116.239228","article-title":"Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine","volume":"361","author":"Fukumoto","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104762_bib30","first-page":"e105","article-title":"Dementia Forecasting Collaborators, 2022. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019","volume":"7","author":"GBD","year":"2019","journal-title":"Lancet Public Health"},{"issue":"13","key":"10.1016\/j.neubiorev.2022.104762_bib31","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1172\/JCI143774","article-title":"Targeting the gut to treat multiple sclerosis","volume":"131","author":"Ghezzi","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104762_bib32","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1212\/WNL.0000000000002898","article-title":"Detecting depression in Parkinson disease: A systematic review and meta-analysis","volume":"87","author":"Goodarzi","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104762_bib33","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1124\/pharmrev.120.000133","article-title":"Therapeutics in the pipeline targeting alpha-synuclein for Parkinson\u2019s disease","volume":"74","author":"Grosso Jasutkar","year":"2022","journal-title":"Pharmacol. Rev."},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104762_bib34","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1212\/WNL.0000000000001684","article-title":"Depression and subsequent risk of Parkinson's disease; a nationwide cohort study","volume":"84","author":"Gustafsson","year":"2015","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104762_bib35","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00406-016-0692-7","article-title":"Reduction of dopamine D2\/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: A PET study in conscious monkeys","volume":"267","author":"Hashimoto","year":"2017","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"10","key":"10.1016\/j.neubiorev.2022.104762_bib36","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/pcn.12902","article-title":"Rapid-acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective","volume":"73","author":"Hashimoto","year":"2019","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.neubiorev.2022.104762_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113935","article-title":"Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine","volume":"177","author":"Hashimoto","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"21","key":"10.1016\/j.neubiorev.2022.104762_bib38","doi-asserted-by":"crossref","first-page":"11200","DOI":"10.1073\/pnas.2001264117","article-title":"Are NMDA and opioid receptors involved in the antidepressant actions of ketamine?","volume":"117","author":"Hashimoto","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neubiorev.2022.104762_bib39","first-page":"27","article-title":"Ketamine: anesthetic, psychotomimetic, antidepressant, or anthelmintic","author":"Hashimoto","year":"2022","journal-title":"Mol. Psychiatry 2022 Apr"},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104762_bib40","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1017\/S1092852915000929","article-title":"Comorbidity between neurological illness and psychiatric disorders","volume":"21","author":"Hesdorffer","year":"2016","journal-title":"CNS Spectr."},{"issue":"5","key":"10.1016\/j.neubiorev.2022.104762_bib41","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1192\/bjp.2020.89","article-title":"Are we repeating mistakes of the past? A review of the evidence for esketamine","volume":"219","author":"Horowitz","year":"2021","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104762_bib42","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nprot.2006.342","article-title":"Protocol for the MPTP mouse model of Parkinson\u2019s disease","volume":"2","author":"Jackson-Lewis","year":"2007","journal-title":"Nat. Protoc."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104762_bib43","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/0269881120959644","article-title":"Ketamine: A tale of two enantiomers","volume":"35","author":"Jelen","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2022.104762_bib44","doi-asserted-by":"crossref","first-page":"102904","DOI":"10.1016\/j.msard.2021.102904","article-title":"Depression in multiple sclerosis: Is one approach for its management enough?","volume":"51","author":"Jones","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.neubiorev.2022.104762_bib45","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1038\/mp.2017.109","article-title":"Acute ketamine administration corrects abnormal inflammatory bone markers in major depressive disorder","volume":"23","author":"Kadriu","year":"2018","journal-title":"Mol. Psychiatry"},{"issue":"7","key":"10.1016\/j.neubiorev.2022.104762_bib46","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1017\/S0033291716000064","article-title":"Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories","volume":"46","author":"Kishimoto","year":"2016","journal-title":"Psychol. Med."},{"issue":"5","key":"10.1016\/j.neubiorev.2022.104762_bib47","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.neuron.2019.02.005","article-title":"Ketamine: A paradigm shift for depression research and treatment","volume":"101","author":"Krystal","year":"2019","journal-title":"Neuron"},{"issue":"14","key":"10.1016\/j.neubiorev.2022.104762_bib48","doi-asserted-by":"crossref","first-page":"7421","DOI":"10.3390\/ijms22147421","article-title":"Molecular basis of late-life depression","volume":"22","author":"Kuo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104762_bib49","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00406-020-01110-5","article-title":"Intravenous arketamine for treatment-resistant depression: open-label pilot study","volume":"271","author":"Leal","year":"2021","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.neubiorev.2022.104762_bib50","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.euroneuro.2022.02.004","article-title":"Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how","volume":"57","author":"Lengvenyte","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.neubiorev.2022.104762_bib51","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.parkreldis.2020.09.024","article-title":"Unmet needs in Parkinson disease: Motor and non-motor","volume":"80","author":"LeWitt","year":"2020","journal-title":"Park. Relat. Disord."},{"issue":"5","key":"10.1016\/j.neubiorev.2022.104762_bib52","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/s41386-021-01242-9","article-title":"Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial","volume":"47","author":"Lijffijt","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neubiorev.2022.104762_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuron.2022.05.027","article-title":"The role of hippocampal KCNQ2 channel in antidepressant actions of ketamine","author":"Ma","year":"2022","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104762_bib54","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41398-022-01803-6","article-title":"Nuclear factor of activated T cells 4 in the prefrontal cortex is required for prophylactic actions of (R)-ketamine","volume":"12","author":"Ma","year":"2022","journal-title":"Transl. Psychiatry"},{"issue":"12","key":"10.1016\/j.neubiorev.2022.104762_bib55","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11920-017-0855-x","article-title":"Use of ketamine in elderly patients with treatment-resistant depression","volume":"19","author":"Medeiros da Frota Ribeiro","year":"2017","journal-title":"Curr. Psychiatry Rep."},{"issue":"1\u20132","key":"10.1016\/j.neubiorev.2022.104762_bib56","first-page":"56","article-title":"Ketamine therapy for treatment-resistant depression in a patient with multiple sclerosis: A case report","volume":"14","author":"Messer","year":"2017","journal-title":"Innov. Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104762_bib57","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3390\/neurolint14020025","article-title":"The possible application of ketamine in the treatment of depression in Alzheimer\u2019s disease","volume":"14","author":"Mohammad Shehata","year":"2022","journal-title":"Neurol. Int."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104762_bib58","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1161\/STROKEAHA.113.002999","article-title":"Bone mineral density and incidence of stroke: European prospective investigation into cancer-norfolk population-based study, systematic review, and meta-analysis","volume":"45","author":"Myint","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.neubiorev.2022.104762_bib59","first-page":"950","article-title":"Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression","volume":"172","author":"Newport","year":"2015"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104762_bib60","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/s12325-020-01570-0","article-title":"Annual cost burden by level of relapse severity in patients with multiple sclerosis","volume":"38","author":"Nicholas","year":"2021","journal-title":"Adv. Ther."},{"issue":"5","key":"10.1016\/j.neubiorev.2022.104762_bib61","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1176\/appi.ajp.21111086","article-title":"Au update on community ketamine practices","volume":"179","author":"O\u2019Brien","year":"2022","journal-title":"Am. J. Psychiatry"},{"issue":"8","key":"10.1016\/j.neubiorev.2022.104762_bib62","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1007\/s00429-021-02354-0","article-title":"Structural connectivity and subcellular changes after antidepressant doses of ketamine and Ro 25-6981 in the rat: an MRI and immuno-labeling study","volume":"226","author":"Pascual-Ant\u00f3n","year":"2021","journal-title":"Brain Struct. Funct."},{"key":"10.1016\/j.neubiorev.2022.104762_bib63","first-page":"10","article-title":"Use of antidepressants in unipolar depression in the elderly","author":"Pericaud","year":"2022","journal-title":"Enceph. 2022 Feb"},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104762_bib64","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00406-020-01208-w","article-title":"Rapid-acting and long-lasting antidepressant-like action of (R)-ketamine in Nrf2 knock-out mice: a role of TrkB signaling","volume":"271","author":"Qu","year":"2021","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104762_bib65","doi-asserted-by":"crossref","first-page":"15725","DOI":"10.1038\/s41598-017-16060-7","article-title":"Comparison of (R)-ketamine and lanicemine on depression-like phenotype and abnormal composition of gut microbiota in a social defeat stress model","volume":"7","author":"Qu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neubiorev.2022.104762_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2021.113633","article-title":"The effectiveness of (R)-ketamine and its mechanism of action differ from those of (S)-ketamine in a chronic unpredictable mild stress model of depression in C57BL\/6J mice","volume":"418","author":"Rafa\u0142o-Uli\u0144ska","year":"2022","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neubiorev.2022.104762_bib67","first-page":"22","article-title":"Multiple sclerosis caregiving: A systematic scoping review to map current state of knowledge","author":"Rajachandrakumar","year":"2021","journal-title":"Health Soc. Care. Community 2021 Dec."},{"issue":"25","key":"10.1016\/j.neubiorev.2022.104762_bib68","doi-asserted-by":"crossref","first-page":"E5815","DOI":"10.1073\/pnas.1802179115","article-title":"Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson\u2019s disease","volume":"115","author":"Ren","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104762_bib69","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1001\/jamapsychiatry.2021.4377","article-title":"Longitudinal associations of mental disorders with dementia: 30-year analysis of 1.7 million New Zealand citizens","volume":"79","author":"Richmond-Rakerd","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"24","key":"10.1016\/j.neubiorev.2022.104762_bib70","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.3390\/jcm10245912","article-title":"Selective serotonin reuptake inhibitors for the prevention of post-stroke depression: A systematic review and meta-analysis","volume":"10","author":"Richter","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.neubiorev.2022.104762_bib71","doi-asserted-by":"crossref","first-page":"i48","DOI":"10.1136\/jnnp.2004.060426","article-title":"Depression in neurological disorders: Parkinson\u2019s disease, multiple sclerosis, and stroke","volume":"Suppl 1","author":"Rickards","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry 76("},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104762_bib72","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.bone.2012.05.018","article-title":"Antidepressant medications and osteoporosis","volume":"51","author":"Rizzoli","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.neubiorev.2022.104762_bib73","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1176\/appi.ajp.2015.15030363","article-title":"Post-stroke depression: a review","volume":"173","author":"Robinson","year":"2016","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104762_bib74","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/YIC.0000000000000334","article-title":"Use of subcutaneous ketamine to rapidly improve severe treatment-resistant depression in a patient with Alzheimer\u2019s disease","volume":"36","author":"Rocha","year":"2021","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.neubiorev.2022.104762_bib75","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00002508-200409000-00016","article-title":"Multiple sclerosis with severe pain and allodynia alleviated by oral ketamine","volume":"20","author":"Sakai","year":"2004","journal-title":"Clin. J. Pain."},{"issue":"8","key":"10.1016\/j.neubiorev.2022.104762_bib76","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nrn.2017.62","article-title":"Non-motor features of Parkinson\u2019s disease","volume":"18","author":"Schapira","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neubiorev.2022.104762_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.114963","article-title":"Is (R)-ketamine a potential therapeutic agent for treatment-resistant depression with less detrimental side effects? A review of molecular mechanisms underlying ketamine and its enantiomers","volume":"198","author":"Scotton","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neubiorev.2022.104762_bib78","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.brainresbull.2021.09.009","article-title":"Regulation of neurotoxicity in the striatum and colon of MPTP-induced Parkinson\u2019s disease mice by gut microbiome","volume":"177","author":"Shan","year":"2021","journal-title":"Brain Res. Bull."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104762_bib79","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000444278","article-title":"Case reports showing a long-term effect of subanesthetic ketamine infusion in reducing L-DOPA-induced dyskinesias","volume":"8","author":"Sherman","year":"2016","journal-title":"Case Rep. Neurol."},{"issue":"6","key":"10.1016\/j.neubiorev.2022.104762_bib80","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2015.10.018","article-title":"Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study","volume":"80","author":"Singh","year":"2016","journal-title":"Biol. Psychiatry"},{"issue":"13","key":"10.1016\/j.neubiorev.2022.104762_bib81","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1038\/npp.2017.94","article-title":"Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression","volume":"42","author":"Su","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neubiorev.2022.104762_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2019.172839","article-title":"Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent repeated intermittent administration of (R)-ketamine, but not (S)-ketamine: role of BDNF-TrkB signaling","volume":"188","author":"Tan","year":"2020","journal-title":". Pharmacol. Biochem. Behav."},{"issue":"Jan 3","key":"10.1016\/j.neubiorev.2022.104762_bib83","article-title":"Repeated intermittent administration of (R)-ketamine during juvenile and adolescent stages prevents schizophrenia-relevant phenotypes in adult offspring after maternal immune activation: a role of TrkB signaling","volume":"2022","author":"Tan","year":"2022","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.neubiorev.2022.104762_bib84","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jad.2020.03.040","article-title":"Risk of psychosis after repeated intermittent administration of (S)-ketamine, but not (R)-ketamine, in mice","volume":"269","author":"Tan","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neubiorev.2022.104762_bib85","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1600-0404.2008.01036.x","article-title":"The cuprizone model for demyelination","volume":"188","author":"Torkildsen","year":"2008","journal-title":"Acta Neurol. Scand. Suppl."},{"issue":"12","key":"10.1016\/j.neubiorev.2022.104762_bib86","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S2215-0366(19)30394-3","article-title":"Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval","volume":"6","author":"Turner","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.neubiorev.2022.104762_bib87","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.brainresbull.2020.12.011","article-title":"Ketamine reversed short-term memory impairment and depressive-like behavior in animal model of Parkinson's disease","volume":"168","author":"Vecchia","year":"2021","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neubiorev.2022.104762_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109139","article-title":"Effects of (R)-ketamine on reduced bone mineral density in ovariectomized mice: A role of gut microbiota","volume":"213","author":"Wan","year":"2022","journal-title":"Neuropharmacology"},{"issue":"15","key":"10.1016\/j.neubiorev.2022.104762_bib89","doi-asserted-by":"crossref","first-page":"7802","DOI":"10.3390\/ijms22157802","article-title":"MicroRNAs, multiple sclerosis, and depression","volume":"22","author":"Wang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neubiorev.2022.104762_bib90","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.brainresbull.2021.10.013","article-title":"(R)-ketamine ameliorates the progression of experimental autoimmune encephalomyelitis in mice","volume":"177","author":"Wang","year":"2021","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neubiorev.2022.104762_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105635","article-title":"(R)-ketamine ameliorates demyelination and facilitates remyelination in cuprizone-treated mice: A role of gut-microbiota-brain axis","volume":"165","author":"Wang","year":"2022","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neubiorev.2022.104762_bib92","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.pnpbp.2018.05.025","article-title":"Association between depression and the subsequent risk of Parkinson's disease: A meta-analysis","volume":"86","author":"Wang","year":"2018","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"9834","key":"10.1016\/j.neubiorev.2022.104762_bib93","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/S0140-6736(12)60738-7","article-title":"Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis","volume":"379","author":"Wardlaw","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.neubiorev.2022.104762_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172870","article-title":"A historical review of antidepressant effects of ketamine and its enantiomers","volume":"190","author":"Wei","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104762_bib95","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41380-021-01121-1","article-title":"Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor","volume":"27","author":"Wei","year":"2022","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104762_bib96","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1176\/appi.ajp.2017.17040472","article-title":"The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis","volume":"175","author":"Wilkinson","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neubiorev.2022.104762_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172904","article-title":"Neuronal brain injury after cerebral ischemic stroke is ameliorated after subsequent administration of (R)-ketamine, but not (S)-ketamine","volume":"191","author":"Xiong","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neubiorev.2022.104762_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2019.111904","article-title":"Beneficial effects of (R)-ketamine, but not its metabolite (2R,6R)-hydroxynorketamine, in the depression-like phenotype, inflammatory bone markers, and bone mineral density in a chronic social defeat stress model","volume":"368","author":"Xiong","year":"2019","journal-title":"Behav. Brain Res."},{"issue":"9","key":"10.1016\/j.neubiorev.2022.104762_bib99","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1001\/jamaneurol.2014.1210","article-title":"Symptomatic intracerebral hemorrhage in acute ischemic stroke after thrombolysis with intravenous recombinant tissue plasminogen activator: a review of natural history and treatment","volume":"271","author":"Yaghi","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neubiorev.2022.104762_bib100","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.psychres.2016.03.034","article-title":"Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine","volume":"239","author":"Yang","year":"2016","journal-title":"Psychiatry Res"},{"issue":"5","key":"10.1016\/j.neubiorev.2022.104762_bib101","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.biopsych.2016.12.020","article-title":"(R)-ketamine shows greater potency and longer lasting antidepressant effects than its metabolite (2R,6R)-hydroxynorketamine","volume":"82","author":"Yang","year":"2017","journal-title":"Biol. Psychiatry"},{"issue":"12","key":"10.1016\/j.neubiorev.2022.104762_bib102","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/s41398-017-0031-4","article-title":"Possible role of the gut microbiota-brain axis in the antidepressant effects of (R)-ketamine in a social defeat stress model","volume":"7","author":"Yang","year":"2017","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104762_bib103","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.biopsych.2017.05.016","article-title":"Mechanistic target of rapamycin-independent antidepressant effects of (R)-ketamine in a social defeat stress model","volume":"83","author":"Yang","year":"2018","journal-title":"Biol. Psychiatry"},{"issue":"9","key":"10.1016\/j.neubiorev.2022.104762_bib104","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.136","article-title":"R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects","volume":"5","author":"Yang","year":"2015","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104762_bib105","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41398-019-0624-1","article-title":"Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites","volume":"9","author":"Yang","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neubiorev.2022.104762_bib106","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41531-020-0117-1","article-title":"Current and projected future economic burden of Parkinson\u2019s disease in the U.S","volume":"6","author":"Yang","year":"2020","journal-title":"NPJ Park. Dis."},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104762_bib107","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/s41380-021-01377-7","article-title":"Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine","volume":"27","author":"Yao","year":"2022","journal-title":"Mol. Psychiatry"},{"issue":"11","key":"10.1016\/j.neubiorev.2022.104762_bib108","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1136\/jnnp-2019-321913","article-title":"Evidence-based prevention of Alzheimer\u2019s disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomized controlled trials","volume":"91","author":"Yu","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"7604","key":"10.1016\/j.neubiorev.2022.104762_bib109","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.neubiorev.2022.104762_bib110","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neubiorev.2022.104762_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119882","article-title":"(R)-Ketamine ameliorates lethal inflammatory responses and multi-organ injury in mice induced by cecum ligation and puncture","volume":"284","author":"Zhang","year":"2021","journal-title":"Life Sci."},{"issue":"10","key":"10.1016\/j.neubiorev.2022.104762_bib112","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1007\/s00213-021-05889-6","article-title":"(R)-Ketamine attenuates LPS-induced endotoxin-derived delirium through inhibition of neuroinflammation","volume":"238","author":"Zhang","year":"2021","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.neubiorev.2022.104762_bib113","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.pbb.2013.11.033","article-title":"R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine","volume":"116","author":"Zhang","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104762_bib114","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/14737175.2019.1554434","article-title":"An update on ketamine and its two enantiomers as rapid-acting antidepressants","volume":"19","author":"Zhang","year":"2019","journal-title":"Expert Rev. Neurother."},{"issue":"11","key":"10.1016\/j.neubiorev.2022.104762_bib115","first-page":"1025","article-title":"Role of inflammatory bone markers in the antidepressant actions of (R)-ketamine in a chronic social defeat stress model","volume":"21","author":"Zhang","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104762_bib116","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00406-019-01092-z","article-title":"Splenic NKG2D confers resilience versus susceptibility in mice after chronic social defeat stress: beneficial effects of (R)-ketamine","volume":"271","author":"Zhang","year":"2021","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104762_bib117","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41398-020-0733-x","article-title":"Essential role of microglial transforming growth factor-\u03b21 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-\u03b21","volume":"10","author":"Zhang","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neubiorev.2022.104762_bib118","first-page":"10","article-title":"Systematic evaluation of the associations between mental disorders and dementia: An umbrella review of systematic reviews and meta-analyses","author":"Zhao","year":"2022","journal-title":"J. Affect. Disord."},{"issue":"13","key":"10.1016\/j.neubiorev.2022.104762_bib119","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.3390\/ijerph17134710","article-title":"Assessment of ketamine and its enantiomers in an organophosphate-based rat model for features of Gulf War illness","volume":"17","author":"Zhu","year":"2020","journal-title":"Int. J. Environ. Res. Public Health"}],"container-title":["Neuroscience & Biobehavioral Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763422002512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763422002512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:20:45Z","timestamp":1758968445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149763422002512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":119,"alternative-id":["S0149763422002512"],"URL":"https:\/\/doi.org\/10.1016\/j.neubiorev.2022.104762","relation":{},"ISSN":["0149-7634"],"issn-type":[{"value":"0149-7634","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"(R)-ketamine as prophylactic and therapeutic drug for neurological disorders: Beyond depression","name":"articletitle","label":"Article Title"},{"value":"Neuroscience & Biobehavioral Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neubiorev.2022.104762","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104762"}}